Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPD008
MIFTS: 64

Lipid Metabolism Disorder

Categories: Immune diseases, Liver diseases, Metabolic diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lipid Metabolism Disorder

About this section

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Dyslipidemia 12 55 15
Disorder of Fatty Acid Metabolism 29 73
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 43 73
Lipid Metabolism, Inborn Errors 44
Fatty Acid Metabolism Disorder 12
Dyslipidemias 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Neuronal diseases Immune diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3146
MeSH 44 D008052
ICD10 33 E71.3
Sources

Summaries for Lipid Metabolism Disorder

About this section
MedlinePlus : 43 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to fatty liver disease, nonalcoholic 1 and abdominal obesity-metabolic syndrome 1. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Simvastatin and Fenofibrate have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 76 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the break down or... more...

Sources

Related Diseases for Lipid Metabolism Disorder

About this section

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 325)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 32.3 ADIPOQ INS LEP MTTP PPARA
2 abdominal obesity-metabolic syndrome 1 32.0 ADIPOQ INS LEP MTTP PPARG
3 chylomicron retention disease 31.7 APOA1 APOB MTTP
4 sitosterolemia 31.7 APOB HMGCR MTTP
5 hyperlipoproteinemia, type iv 31.7 APOA5 APOB APOC3 LPL
6 familial lipoprotein lipase deficiency 31.6 APOA5 APOC3 LIPC LPL
7 prediabetes syndrome 31.4 ADIPOQ APOB COG2 CRP INS LEP
8 hypoalphalipoproteinemia, primary 31.4 APOA1 APOB APOC3 CETP LIPC LPL
9 hyperlipoproteinemia, type v 31.3 APOA1 APOA5 APOB APOE HMGCR INS
10 hypolipoproteinemia 31.3 APOA1 APOB APOE LPA LPL MTTP
11 hyperlipoproteinemia, type iii 31.1 APOA1 APOA5 APOB APOE CETP COG2
12 hyperglycemia 30.8 ADIPOQ INS LEP PPARG
13 liver disease 30.8 ADIPOQ INS LEP PPARA
14 familial hyperlipidemia 30.7 APOA1 APOB APOC3 APOE CETP COG2
15 hyperinsulinism 30.5 APOB INS LEP
16 chronic kidney failure 30.3 ADIPOQ APOB CRP HMGCR INS LEP
17 gestational diabetes 30.3 ADIPOQ INS LEP RBP4
18 nonalcoholic steatohepatitis 30.2 ADIPOQ INS LEP
19 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.2 ADIPOQ INS
20 glucose intolerance 30.2 ADIPOQ APOB CRP INS LEP LPL
21 sleep apnea 30.1 ADIPOQ APOE CRP INS LEP
22 hyperuricemia 30.1 APOB CRP INS
23 coronary artery anomaly 30.0 APOA1 APOA5 APOB CETP COG2 CRP
24 hyperlipidemia, familial combined 29.9 APOA1 APOA5 APOB APOC3 COG2 LPA
25 nonalcoholic fatty liver disease 29.9 ADIPOQ APOB CRP INS LEP MTTP
26 anovulation 29.9 CRP INS LEP
27 amyloidosis aa 29.9 APOA1 CRP LPA
28 fatty liver disease 29.9 ADIPOQ INS LEP PPARA
29 diabetes mellitus 29.8 ADIPOQ APOA1 APOA5 APOB COG2 CRP
30 arteries, anomalies of 29.8 ADIPOQ APOA1 APOB APOE CETP COG2
31 homozygous familial hypercholesterolemia 29.8 APOB APOE HMGCR LIPC MTTP
32 severe pre-eclampsia 29.7 ADIPOQ LEP RBP4
33 ischemic heart disease 29.7 APOA1 APOB APOE CRP LPL
34 hypertension, essential 29.7 ADIPOQ APOA1 APOB CRP INS LEP
35 acanthosis nigricans 29.6 ADIPOQ INS LEP PPARG
36 atherosclerosis susceptibility 29.6 ADIPOQ APOA1 APOB APOE CETP CRP
37 tangier disease 29.6 APOA1 APOB APOE CETP LPA LPL
38 heart disease 29.6 APOA1 APOA5 APOB APOC3 APOE CRP
39 osteoporosis 29.6 ADIPOQ APOE CRP HMGCR INS LEP
40 peripheral vascular disease 29.6 APOA1 APOB CRP LPA
41 gallbladder disease 29.6 APOA1 APOB APOE CETP INS
42 kidney disease 29.5 ADIPOQ APOC3 APOE CRP HMGCR INS
43 uremia 29.5 APOC3 CRP INS LEP LPL
44 diabetes mellitus, insulin-dependent 29.5 APOA1 APOB INS LEP LPA
45 vascular disease 29.5 ADIPOQ APOA1 APOB APOE CETP CRP
46 xanthomatosis 29.5 APOB APOE HMGCR LPA LPL
47 hypertriglyceridemia, familial 29.4 APOA1 APOA5 APOB APOC3 APOE CETP
48 arcus corneae 29.4 APOA1 APOB APOE CETP COG2 LPA
49 carotid artery disease 29.4 APOA1 APOB APOE COG2 CRP LPA
50 myocardial infarction 29.4 ADIPOQ APOA1 APOA5 APOB APOC3 APOE

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder
Sources

Symptoms & Phenotypes for Lipid Metabolism Disorder

About this section

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOA1 APOA5 APOB APOC3 APOE CETP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 ADIPOQ APOA1 APOB APOE CRP INS
2 homeostasis/metabolism MP:0005376 10.19 ADIPOQ APOA1 APOA5 APOB APOE COG2
3 cellular MP:0005384 10.14 ADIPOQ APOA1 APOB APOE FADS1 INS
4 growth/size/body region MP:0005378 10.06 ADIPOQ APOB APOE COG2 HMGCR INS
5 endocrine/exocrine gland MP:0005379 10.02 ADIPOQ APOA1 APOE FADS1 INS LEP
6 adipose tissue MP:0005375 10 ADIPOQ APOE INS LEP LPL PPARA
7 integument MP:0010771 9.76 ADIPOQ APOA1 APOE INS LEP LPL
8 liver/biliary system MP:0005370 9.7 ADIPOQ APOA1 APOB APOE HMGCR INS
9 muscle MP:0005369 9.28 ADIPOQ APOB APOE INS LEP LPL
Sources

Drugs & Therapeutics for Lipid Metabolism Disorder

About this section

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 674)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
2
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 49562-28-9 3339
3
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
4
Probucol Approved, Investigational Phase 4,Phase 3 23288-49-5 4912
5
Cilostazol Approved, Investigational Phase 4,Phase 1 73963-72-1 2754
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
7
Fluvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 93957-54-1 1548972
8
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-92-0 936
9
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
11
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
12
Thrombin Approved, Investigational Phase 4
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81093-37-0 54687
15
Abacavir Approved, Investigational Phase 4,Phase 2,Not Applicable 136470-78-5 65140 441300
16
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
17
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
18
Nevirapine Approved Phase 4,Phase 2,Not Applicable 129618-40-2 4463
19
Lopinavir Approved Phase 4,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
20
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
21
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
22
Pitavastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147511-69-1, 147526-32-7 5282452 6366718
23
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
24
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
25 Orange Approved Phase 4,Phase 1,Not Applicable
26
Lovastatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75330-75-5 53232
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
28
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 24280-93-1 446541
29
Bezafibrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 41859-67-0 39042
30
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
31
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 154598-52-4 64139
32
Darunavir Approved Phase 4,Phase 1 206361-99-1, 635728-49-3 213039
33
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 144701-48-4 65999
34 Fenofibric acid Approved Phase 4,Phase 3,Phase 1,Not Applicable 42017-89-0
35
Bilberry Approved, Experimental Phase 4,Phase 3,Not Applicable
36
Gemfibrozil Approved Phase 4,Phase 1 25812-30-0 3463
37
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
38
Methylcobalamin Approved, Experimental, Investigational Phase 4,Not Applicable 13422-55-4
39
Emtricitabine Approved, Investigational Phase 4,Not Applicable 143491-57-0 60877
40
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
41
Calcium polycarbophil Approved Phase 4,Not Applicable 126040-58-2
42
Loperamide Approved Phase 4,Not Applicable 53179-11-6 3955
43
Colestipol Approved Phase 4 26658-42-4
44
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
45
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 46835353 6436030 5284616
46
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
47
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
48
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
49
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
50
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8007-45-2

Interventional clinical trials:

(show top 50) (show all 2656)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
2 An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Self-Assessment Method for Statin Side-effects Or Nocebo Unknown status NCT02668016 Phase 4 Atorvastatin
4 Nutraceuticals to Improve Lipid Profile in European Countries Unknown status NCT01649986 Phase 4 Nutraceuticals (Armolipid Plus)
5 Treatment of Hyperlipidemia and Sexual Dysfunction Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
6 Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe Unknown status NCT02772640 Phase 4 Rosuvastatin and Ezetimibe morning or evening administration
7 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
8 Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia Unknown status NCT01849185 Phase 4
9 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
10 Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia Unknown status NCT00972829 Phase 4 Rosuvastatin;Ezetimibe
11 Triglyceride Lowering Study Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
12 Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia Unknown status NCT00746811 Phase 4 P-OM3;Placebo
13 Fluvastatin After Heart Transplantation Unknown status NCT00421005 Phase 4 fluvastatin
14 Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? Unknown status NCT00295373 Phase 4 Rosuvastatin
15 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
16 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
17 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
18 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
19 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
20 The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
21 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
22 Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia Unknown status NCT01480687 Phase 4 Ciprofibrate
23 Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes Unknown status NCT01322711 Phase 4 Atorvastatin;Placebo
24 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
25 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
26 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
27 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
28 Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
29 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
30 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
31 Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
32 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
33 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
34 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
35 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
36 The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control Unknown status NCT00282659 Phase 4 magnesium L-lactate
37 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
38 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
39 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED) Completed NCT00651963 Phase 4 ezetimibe
40 Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Completed NCT01551173 Phase 4 Fluvastatin sodium
41 Pharmacological Regulation of Fat Transport in Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
42 Regulation of Lipoprotein Transport in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
43 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
44 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
45 Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects Completed NCT01385020 Phase 4 Gemfibrozil & red yeast rice (LipoCol)
46 Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females Completed NCT03615534 Phase 4 Fenofibrate
47 Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial Completed NCT03221816 Phase 4 Tenavit®;Placebo Oral Tablet
48 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed NCT02642159 Phase 4 Alirocumab;Statins;Ezetimibe;Fenofibrate;Nicotinic acid;Omega-3 fatty acids;Antihyperglycemic Drug
49 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed NCT02442700 Phase 4 pitavastatin;placebo
50 The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients Completed NCT02103049 Phase 4 Ezetimibe

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Sources

Genetic Tests for Lipid Metabolism Disorder

About this section

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29
Sources

Anatomical Context for Lipid Metabolism Disorder

About this section

MalaCards organs/tissues related to Lipid Metabolism Disorder:

41
Liver, Heart, Kidney, Endothelial, Testes, Ovary, Bone
Sources

Publications for Lipid Metabolism Disorder

About this section

Articles related to Lipid Metabolism Disorder:

(show top 50) (show all 947)
# Title Authors Year
1
Dermal microvessel density and maturity is closely associated with atherogenic dyslipidemia and accumulation of advanced glycation end products in adult patients with type 1 diabetes. ( 30312628 )
2019
2
The cross-sectional and longitudinal associations of chromium with dyslipidemia: A prospective cohort study of urban adults in China. ( 30336313 )
2019
3
Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( 30343038 )
2019
4
Identification of 12 novel loci that confer susceptibility to early-onset dyslipidemia. ( 30365130 )
2019
5
Polystyrene microplastics induce gut microbiota dysbiosis and hepatic lipid metabolism disorder in mice. ( 29529433 )
2018
6
Curcumin Attenuates Lipopolysaccharide-Induced Hepatic Lipid Metabolism Disorder by Modification of m<sup>6</sup> A RNA Methylation in Piglets. ( 29488640 )
2018
7
Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. ( 30474346 )
2018
8
Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR. ( 30167772 )
2018
9
Aging and Hyperglycemia Intensify Dyslipidemia-Induced Oxidative Stress and Inflammation in Rats: Assessment of Restorative Potentials of ALA and EPA + DHA. ( 30535619 )
2018
10
Alström syndrome: Renal findings in correlation with obesity, insulin resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively evaluated at the NIH clinical center. ( 30064963 )
2018
11
Suppressing Irf2bp2 expressions accelerates metabolic syndrome-associated brain injury and hepatic dyslipidemia. ( 30131248 )
2018
12
Umbilical Cord Blood Metabolomics Reveal Distinct Signatures of Dyslipidemia Prior to Bronchopulmonary Dysplasia and Pulmonary Hypertension. ( 30113229 )
2018
13
Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice. ( 30286142 )
2018
14
Gut microbiota dysbiosis correlates with a low-dose PCB126-induced dyslipidemia and non-alcoholic fatty liver disease. ( 30412872 )
2018
15
Prolonged PM2.5 exposure elevates risk of oxidative stress-driven nonalcoholic fatty liver disease by triggering increase of dyslipidemia. ( 30465824 )
2018
16
Dyslipidemia and Fatty Liver Disease in Overweight and Obese Children. ( 30009050 )
2018
17
Dyslipidemia is associated with pediatric nonalcoholic fatty liver disease. ( 29699915 )
2018
18
Previous Gestational Diabetes Increases Atherogenic Dyslipidemia in Subsequent Pregnancy and Postpartum. ( 29732563 )
2018
19
Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II CHD). ( 30355016 )
2018
20
Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. ( 30198749 )
2018
21
Coating rice with mulberry leaves rich in deoxynojirimycin ameliorates hyperglycemia and dyslipidemia in C57BL/KsJ db/db mice. ( 30515274 )
2018
22
Beneficial Effects of Poplar Buds on Hyperglycemia, Dyslipidemia, Oxidative Stress, and Inflammation in Streptozotocin-Induced Type-2 Diabetes. ( 30320140 )
2018
23
Modulation of hyperglycemia and dyslipidemia in experimental type 2 diabetes by gallic acid and p-coumaric acid: The role of adipocytokines and PPARγ. ( 30021345 )
2018
24
The effects of hydroalcoholic extract of Allium elburzense Wendelbo bulb on dexamethasone-induced dyslipidemia, hyperglycemia, and oxidative stress in rats. ( 29387108 )
2018
25
Prevalence of high bloodpressure, hyperglycemia, dyslipidemia, metabolic syndrome and their determinants in Ethiopia: Evidences from the National NCDs STEPS Survey, 2015. ( 29742131 )
2018
26
Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats. ( 29750001 )
2018
27
Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. ( 30081468 )
2018
28
Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia. ( 30279893 )
2018
29
Association of Lichen Planopilaris With Dyslipidemia. ( 29998306 )
2018
30
Molecular mechanisms of lipid metabolism disorder in livers of ewes with pregnancy toxemia. ( 30117411 )
2018
31
Lipid metabolism disorder induced by up-regulation of miR-125b and miR-144 following β-diketone antibiotic exposure to F0-zebrafish (Danio rerio). ( 30121499 )
2018
32
Chronic effects of mercury on Bufo gargarizans larvae: Thyroid disruption, liver damage, oxidative stress and lipid metabolism disorder. ( 30145490 )
2018
33
Dietary Genistein Alleviates Lipid Metabolism Disorder and Inflammatory Response in Laying Hens With Fatty Liver Syndrome. ( 30405443 )
2018
34
Insights into a Possible Mechanism Underlying the Connection of Carbendazim-Induced Lipid Metabolism Disorder and Gut Microbiota Dysbiosis in Mice. ( 30496565 )
2018
35
Silica nanoparticles trigger hepatic lipid-metabolism disorder in vivo and in vitro. ( 30519016 )
2018
36
Electroacupuncture Mitigates Skeletal Muscular Lipid Metabolism Disorder Related to High-Fat-Diet Induced Insulin Resistance through the AMPK/ACC Signaling Pathway. ( 30524482 )
2018
37
Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study. ( 30522496 )
2018
38
Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus. ( 29948349 )
2018
39
Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial. ( 30091061 )
2018
40
Identifying potentially common genes between dyslipidemia and osteoporosis using novel analytical approaches. ( 29327327 )
2018
41
Obstructive sleep apnea and dyslipidemia. From animal models to clinical evidence. ( 30476296 )
2018
42
Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus. ( 29516281 )
2018
43
Biphasic dyslipidemia in a patient with painless thyroiditis. ( 30337233 )
2018
44
Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. ( 30149100 )
2018
45
Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. ( 30150141 )
2018
46
Dietary 23-hydroxy ursolic acid protects against atherosclerosis and obesity by preventing dyslipidemia-induced monocyte priming and dysfunction. ( 30015296 )
2018
47
The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. ( 29785308 )
2018
48
Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. ( 29862840 )
2018
49
Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines - Executive summary: A consensus endorsed by the Cardiovascular Risk and Prevention Group of the Portuguese Internal Medicine Society, the Portuguese Atherosclerosis Society, the Portuguese Society of Cardiology, the Portuguese Society of Laboratory Medicine, and the Portuguese Association of Clinical Chemistry. ( 29685846 )
2018
50
Sterol carrier protein-2 deficiency attenuates diet-induced dyslipidemia and atherosclerosis in mice. ( 29700117 )
2018
Sources

Variations for Lipid Metabolism Disorder

About this section

ClinVar genetic disease variations for Lipid Metabolism Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 APOE NM_000041.3(APOE): c.461G> T (p.Arg154Leu) single nucleotide variant Likely pathogenic rs200703101 GRCh38 Chromosome 19, 44908757: 44908757
2 APOE NM_000041.3(APOE): c.461G> T (p.Arg154Leu) single nucleotide variant Likely pathogenic rs200703101 GRCh37 Chromosome 19, 45412014: 45412014
Sources

Expression for Lipid Metabolism Disorder

About this section
Search GEO for disease gene expression data for Lipid Metabolism Disorder.
Sources

Pathways for Lipid Metabolism Disorder

About this section

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Metabolism 66
Show member pathways
 13.82 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
2
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) 66
Show member pathways
 12.75 ADIPOQ APOA1 APOA5 FADS1 HMGCR LEP
3
Metabolism of water-soluble vitamins and cofactors 66
Show member pathways
 12.58 APOA1 APOB APOC3 APOE LPL RBP4
4
Glucose / Energy Metabolism 4
12.37 ADIPOQ APOE INS PPARG
5
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.36 ADIPOQ HMGCR INS LEP PPARG
6
Metabolism of fat-soluble vitamins 66
Show member pathways
 12.26 APOA1 APOB APOC3 APOE LPL RBP4
7
Selenium Micronutrient Network 1
Show member pathways
 12.24 APOA1 APOB APOE CRP INS
9
Lipoprotein metabolism 66
Show member pathways
 12.19 APOA1 APOA5 APOB APOC3 APOE CETP
10
Adipogenesis 1
11.97 ADIPOQ INS LEP LPL PPARA PPARG
11
Binding and Uptake of Ligands by Scavenger Receptors 66
Show member pathways
 11.77 APOA1 APOB APOE
12
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.67 HMGCR INS LPL PPARG RBP4
13
Adipocytokine signaling pathway 37
11.58 ADIPOQ LEP PPARA
14
PPAR signaling pathway 37
11.57 ADIPOQ APOA1 APOA5 APOC3 LPL PPARA
15
Statin Pathway 1
Show member pathways
 11.44 APOA1 APOA5 APOB APOC3 APOE CETP
16
Fat digestion and absorption 37
Show member pathways
 11.38 APOA1 APOB MTTP
17
PPAR Alpha Pathway 1
11.15 APOA1 APOA5 APOC3 PPARA
18
Differentiation of white and brown adipocyte 1
11.11 ADIPOQ LEP PPARG
19
Transcription factor regulation in adipogenesis 1
11.04 ADIPOQ LEP PPARG
Sources

GO Terms for Lipid Metabolism Disorder

About this section

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.98 APOA1 APOA5 APOB APOE INS LIPC
2 collagen-containing extracellular matrix GO:0062023 9.83 ADIPOQ APOA1 APOC3 APOE
3 early endosome GO:0005769 9.81 APOA1 APOB APOC3 APOE
4 low-density lipoprotein particle GO:0034362 9.71 APOA1 APOA5 APOB APOE
5 high-density lipoprotein particle GO:0034364 9.65 APOA1 APOA5 APOE CETP LIPC
6 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
7 endosome lumen GO:0031904 9.54 APOB INS
8 spherical high-density lipoprotein particle GO:0034366 9.49 APOA1 APOC3
9 discoidal high-density lipoprotein particle GO:0034365 9.48 APOA1 APOE
10 intermediate-density lipoprotein particle GO:0034363 9.46 APOA1 APOB APOC3 APOE
11 very-low-density lipoprotein particle GO:0034361 9.43 APOA1 APOA5 APOB APOC3 APOE LPL
12 chylomicron GO:0042627 9.1 APOA1 APOA5 APOB APOC3 APOE LPL
13 extracellular region GO:0005576 10.21 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
14 extracellular space GO:0005615 10.13 ADIPOQ APOA1 APOA5 APOB APOC3 APOE

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Name GO ID Score Top Affiliating Genes
1 lipid catabolic process GO:0016042 9.98 APOB APOC3 LIPC LPL
2 response to ethanol GO:0045471 9.98 ADIPOQ HMGCR LEP RBP4
3 negative regulation of inflammatory response GO:0050728 9.97 ADIPOQ APOA1 APOE PPARA
4 triglyceride metabolic process GO:0006641 9.97 APOA5 APOC3 APOE CETP LPL MTTP
5 cholesterol efflux GO:0033344 9.96 APOA1 APOA5 APOB APOC3 APOE
6 high-density lipoprotein particle remodeling GO:0034375 9.95 APOA1 APOC3 APOE CETP LIPC
7 cholesterol biosynthetic process GO:0006695 9.94 APOA1 APOA5 APOE HMGCR
8 low-density lipoprotein particle remodeling GO:0034374 9.93 APOB APOE CETP LIPC LPA
9 response to organic substance GO:0010033 9.92 APOB FADS1 PPARG
10 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.92 ADIPOQ CETP CRP PPARA PPARG
11 circadian rhythm GO:0007623 9.91 ADIPOQ LEP MTTP
12 cholesterol transport GO:0030301 9.91 APOA1 APOB CETP LIPC
13 positive regulation of lipid biosynthetic process GO:0046889 9.91 APOA1 APOA5 APOE INS
14 triglyceride homeostasis GO:0070328 9.91 APOA1 APOA5 APOC3 APOE CETP LIPC
15 response to insulin GO:0032868 9.9 FADS1 LEP PPARA
16 fatty acid biosynthetic process GO:0006633 9.9 FADS1 LIPC LPL
17 glucose metabolic process GO:0006006 9.89 ADIPOQ INS LEP
18 phospholipid efflux GO:0033700 9.89 APOA1 APOA5 APOC3 APOE
19 phospholipid transport GO:0015914 9.88 APOA1 CETP MTTP
20 chylomicron remnant clearance GO:0034382 9.88 APOB APOC3 APOE LIPC
21 chylomicron assembly GO:0034378 9.88 APOA1 APOB APOC3 APOE MTTP
22 reverse cholesterol transport GO:0043691 9.88 APOA1 APOA5 APOC3 APOE CETP LIPC
23 negative regulation of MAP kinase activity GO:0043407 9.87 ADIPOQ APOE HMGCR
24 lipid homeostasis GO:0055088 9.87 APOE CETP PPARG
25 triglyceride catabolic process GO:0019433 9.87 APOA1 APOA5 APOB APOC3 APOE LIPC
26 lipoprotein transport GO:0042953 9.85 APOB MTTP PPARG
27 high-density lipoprotein particle assembly GO:0034380 9.84 APOA1 APOA5 APOE
28 very-low-density lipoprotein particle assembly GO:0034379 9.83 APOB APOC3 MTTP
29 negative regulation of blood vessel diameter GO:0097756 9.83 CRP HMGCR INS
30 positive regulation of cholesterol esterification GO:0010873 9.83 APOA1 APOA5 APOE
31 chylomicron remodeling GO:0034371 9.83 APOA1 APOB APOC3 APOE LPL
32 regulation of Cdc42 protein signal transduction GO:0032489 9.81 APOA1 APOC3 APOE
33 regulation of cholesterol transport GO:0032374 9.8 APOA1 APOA5 APOE
34 lipoprotein biosynthetic process GO:0042158 9.8 APOA1 APOB APOE
35 regulation of intestinal cholesterol absorption GO:0030300 9.79 APOA1 APOA5 LEP
36 negative regulation of lipid catabolic process GO:0050995 9.75 APOC3 INS
37 positive regulation of cellular protein metabolic process GO:0032270 9.75 ADIPOQ INS
38 positive regulation of insulin receptor signaling pathway GO:0046628 9.75 INS LEP
39 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.75 APOB LPL
40 regulation of fat cell differentiation GO:0045598 9.75 LEP PPARG
41 fatty acid homeostasis GO:0055089 9.75 APOE INS
42 fatty acid oxidation GO:0019395 9.75 ADIPOQ PPARG
43 long-chain fatty acid transport GO:0015909 9.74 APOE PPARG
44 negative regulation of gluconeogenesis GO:0045721 9.74 ADIPOQ INS
45 positive regulation of cholesterol efflux GO:0010875 9.74 ADIPOQ APOE
46 phosphatidylcholine metabolic process GO:0046470 9.74 APOA5 CETP
47 response to dietary excess GO:0002021 9.74 APOE LEP
48 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.73 ADIPOQ APOA1
49 high-density lipoprotein particle clearance GO:0034384 9.73 APOA1 APOE
50 phospholipid homeostasis GO:0055091 9.73 APOA1 CETP

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.88 APOA5 APOB APOE LIPC LPA LPL
2 phospholipid binding GO:0005543 9.85 APOA1 APOA5 APOB APOC3 APOE
3 hormone activity GO:0005179 9.75 ADIPOQ INS LEP
4 low-density lipoprotein particle receptor binding GO:0050750 9.67 APOA5 APOB APOE CRP
5 phospholipid transporter activity GO:0005548 9.65 APOA1 CETP MTTP
6 cholesterol binding GO:0015485 9.65 APOA1 APOA5 APOC3 APOE CETP
7 apolipoprotein binding GO:0034185 9.62 LIPC LPA LPL MTTP
8 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.61 APOA1 APOA5 APOE
9 low-density lipoprotein particle binding GO:0030169 9.57 CRP LIPC
10 phospholipase activity GO:0004620 9.56 LIPC LPL
11 lipase binding GO:0035473 9.55 APOA5 APOB
12 lipid transporter activity GO:0005319 9.55 APOA1 APOB APOE CETP MTTP
13 lipase inhibitor activity GO:0055102 9.54 APOA1 APOC3
14 lipoprotein particle binding GO:0071813 9.52 APOA1 APOE
15 high-density lipoprotein particle receptor binding GO:0070653 9.51 APOA1 APOC3
16 triglyceride binding GO:0017129 9.49 CETP LPL
17 cholesterol transporter activity GO:0017127 9.35 APOA1 APOA5 APOB APOE CETP
18 lipid binding GO:0008289 9.28 APOA1 APOA5 APOB APOC3 APOE CETP
Sources

Sources for Lipid Metabolism Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45